Dermatological Problems and COVID-19

The document outlines the dermatological issues related to COVID-19, including skin manifestations like pernio-like lesions, erythematous rashes, and retiform purpura, which vary with the severity of the disease. It discusses skin damage from prolonged use of personal protective equipment and recommends preventive measures and skin care practices to mitigate these effects. Concerns about the use of immunosuppressive and biological drugs in dermatology patients during the pandemic are addressed, suggesting that these treatments may increase the risk of infection or affect the course of COVID-19, with recommendations for lower doses and the use of targeted biological agents. The document also covers the safety of certain dermatological drugs and treatments during the pandemic, such as antihistamines, oral retinoids, and dupilumab, and discusses the potential benefits of drugs like hydroxychloroquine and azithromycin in treating COVID-19. It emphasizes the need to distinguish drug reactions from infection-related rashes and suggests that topical corticosteroids and antihistamines are generally sufficient for treating cutaneous drug reactions.